JPMorgan Chase & Co. Has $33.10 Million Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

JPMorgan Chase & Co. raised its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 159.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 554,835 shares of the specialty pharmaceutical company’s stock after buying an additional 340,854 shares during the period. JPMorgan Chase & Co. owned 2.64% of ANI Pharmaceuticals worth $33,101,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ANIP. Bank of New York Mellon Corp grew its position in ANI Pharmaceuticals by 10.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 131,156 shares of the specialty pharmaceutical company’s stock worth $8,352,000 after acquiring an additional 12,865 shares during the last quarter. Natixis Advisors LLC acquired a new stake in shares of ANI Pharmaceuticals during the second quarter valued at about $741,000. Rhumbline Advisers grew its holdings in shares of ANI Pharmaceuticals by 15.4% during the second quarter. Rhumbline Advisers now owns 42,170 shares of the specialty pharmaceutical company’s stock worth $2,685,000 after purchasing an additional 5,617 shares during the last quarter. Arizona State Retirement System increased its stake in shares of ANI Pharmaceuticals by 4.7% in the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after buying an additional 211 shares during the period. Finally, Great Lakes Advisors LLC raised its holdings in ANI Pharmaceuticals by 10.6% in the 2nd quarter. Great Lakes Advisors LLC now owns 56,081 shares of the specialty pharmaceutical company’s stock valued at $3,571,000 after buying an additional 5,359 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Raymond James raised their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. Finally, Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $77.71.

ANI Pharmaceuticals Stock Performance

ANIP stock opened at $54.60 on Tuesday. The firm has a market cap of $1.15 billion, a PE ratio of -99.27 and a beta of 0.73. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock has a 50-day moving average price of $56.89 and a 200-day moving average price of $59.26. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The business had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.05 earnings per share. As a group, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,231 shares of company stock valued at $2,434,286 over the last ninety days. 12.70% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.